Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis

Abstract

Background

Lung cancer is one of the most common malignant tumors in the world, and is the leading cause of cancer-related mortality. Although there are no conclusive data to support the survival benefits of early detection or early treatment for recurrence, an early and accurate diagnosis of recurrence is critical to optimize therapy.

Purpose

To compare the diagnostic value of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) using fluorine-18 deoxyglucose (18FDG) with conventional imaging techniques (CITs) for the detection of lung cancer recurrence.

Material and Methods

A meta-analysis was performed, with systematic searches conducted using PubMed and EMBASE databases (up to 31 December 2011). Pooled sensitivity, specificity, and diagnostic odds ratio (DOR) values were calculated for 1035 patients reported in 13 articles. Summary receiver-operating characteristic curves (SROC) were also generated.

Results

The pooled sensitivity (95% CI) for PET, PET/CT, and CITs were 0.94 (0.91–0.97), 0.90 (0.84–0.95), and 0.78 (0.71–0.84), respectively. The pooled specificity (95% CI) for PET, PET/CT, and CITs were 0.84 (0.77–0.89), 0.90 (0.87–0.93), and 0.80 (0.75–0.84), respectively. Regarding sensitivity, lower values were associated with CITs than PET (P = 0.000) and PET/CT (P = 0.005), and there was no significant difference between PET/CT and PET (P = 0.102). Regarding specificity, values for PET/CT and PET were significantly higher than for CITs (both P = 0.000), and there was no significant difference between PET/CT and PET (P = 0.273). In the SROC curves, a better diagnostic accuracy was associated with PET/CT than PET and CITs.

Conclusion

PET/CT and PET were found to be superior modalities for the detection of recurrent lung cancer, and PET/CT was superior to PET.

Keywords

PET integrated PET/CT lung cancer recurrence diagnosis meta-analysis

Get full access to this article

View all access options for this article.

References

Jemal

Murray

Ward

. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10–30.

Parkin

Bray

Ferlay

. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.

Deslauriers

. Current surgical treatment of nonsmall cell lung cancer 2001. Eur Respir J Suppl 2002; 35: 61s–70s.

Haberkorn

Schoenberg

. Imaging of lung cancer with CT, MRT and PET. Lung Cancer 2001; 34(Suppl. 3): S13–23.

Rubins

Unger

Colice

. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007; 132(Suppl. 3): 355S–367S.

Chiu

Chern

. Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg 2003; 125: 1300–1305.

Gorich

Beyer-Enke

Flentje

. Evaluation of recurrent bronchogenic carcinoma by computed tomography. Clinical Imaging 1990; 14: 131–137.

Libshitz

Sheppard

. Filling in of radiation therapy-induced bronchiectatic change: a reliable sign of locally recurrent lung cancer. Radiology 1999; 210: 25–27.

Hoh

Hawkins

Glaspy

. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582–589.

10.

Whiting

Rutjes

Reitsma

. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25–25.

11.

Schelbert

Hoh

Royal

. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998; 39: 1302–1305.

12.

Isasi

Moadel

Blaufox

. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90: 105–112.

13.

Zamora

Abraira

Muriel

. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31–31.

14.

Onishi

Ohno

Koyama

. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Eur J Radiol 2011; 79: 473–479.

15.

Kanzaki

Higashiyama

Maeda

. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg 2010; 10: 1009–1014.

16.

Cho

Lee

. A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg 2010; 139: 1447–1451.

17.

Isobe

Hata

Takai

. Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients. Int J Clin Oncol 2009; 14: 497–501.

18.

Hellwig

Groschel

Graeter

. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006; 33: 13–21.

19.

Keidar

Haim

Guralnik

. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004; 45: 1640–1646.

20.

Hicks

Kalff

MacManus

. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001; 42: 1605–1613.

21.

Bury

Corhay

Duysinx

. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999; 14: 1376–1380.

22.

Takenaka

Ohno

Koyama

. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol 2010; 74: 458–464.

23.

Duhaylongsod

Lowe

Patz

Jr . Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995; 110: 130–139. discussion 9–40.

24.

Patz

Jr Lowe

Hoffman

. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 1994; 191: 379–382.

25.

Lee

Aronchick

Alavi

. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review. Chest 2001; 120: 1791–1797.

26.

De Leyn

Stroobants

De Wever

. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24: 3333–3339.

27.

Deeks

. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157–162.

28.

Satoh

Ohtsuka

. PET/CT imaging in response evaluation of SCLC patients. Lung Cancer 2007; 55: 123–124.

29.

Franzius

. FDG PET: advantages for staging the mediastinum? Lung Cancer 2004; 45(Suppl. 2): S69–74.